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The activation threshold of B cells is tightly regulated by an array of inhibitory and activator 
receptors in such a way that disturbances in their expression can lead to the appearance 
of autoimmunity. The aim of this study was to evaluate the expression of activating and 
inhibitory molecules involved in the modulation of B cell functions in transitional, naive, 
and memory B-cell subpopulations from systemic sclerosis patients. To achieve this, 
blood samples were drawn from 31 systemic sclerosis patients and 53 healthy indi-
viduals. Surface expression of CD86, MHC II, CD19, CD21, CD40, CD22, Siglec 10, 
CD35, and FcγRIIB was determined by flow cytometry. IL-10 production was evaluated 
by intracellular flow cytometry from isolated B cells. Soluble IL-6 and IL-10 levels were 
measured by ELISA from supernatants of stimulated B cells. Systemic sclerosis patients 
exhibit an increased frequency of transitional and naive B cells related to memory B cells 
compared with healthy controls. Transitional and naive B cells from patients express 
higher levels of CD86 and FcγRIIB than healthy donors. Also, B cells from patients show 
high expression of CD19 and CD40, whereas memory cells from systemic sclerosis 
patients show reduced expression of CD35. CD19 and CD35 expression levels associ-
ate with different autoantibody profiles. IL-10+ B cells and secreted levels of IL-10 were 
markedly reduced in patients. In conclusion, systemic sclerosis patients show alterations 
in the expression of molecules involved in B-cell regulation. These abnormalities may be 
determinant in the B-cell hyperactivation observed in systemic sclerosis.
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introduction
Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by an excessive deposi-
tion of extracellular matrix on skin and internal organs, vasculopathy, and the presence of a wide 
spectrum of autoantibodies. This disease is classified into limited cutaneous (lcSSc) and diffuse 
cutaneous (dcSSc) according to the degree of skin sclerosis, the presence of interstitial lung disease 
or pulmonary arterial hypertension, and the autoantibody profile (1). Fibrosis in SSc is produced by 
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a dysregulated reparation process, marked by the differentiation 
of tissue fibroblasts to myofibroblasts (2). When the gene expres-
sion pattern of SSc fibroblasts was compared with that of healthy 
individuals, no major differences were observed, which suggests 
that fibrosis could be caused by exogenous stimuli, such as those 
provided by the immune system (3). In that work, an increase in 
the expression of B cell-related genes together with an infiltration 
of CD20+ B cells was observed in SSc skin, suggesting a patho-
genic role of B cells.
Like most cells of the immune system, B cells express a wide 
array of activating and inhibitory receptors that modulate their 
activation status, allowing protective but controlled humoral 
immune responses. Abnormalities in the expression or function 
of these receptors on B cells have been reported in murine models 
of autoimmunity or in patients with autoimmune diseases (4–7). 
CD19 is a cell-surface signal transduction molecule that forms a 
complex with CD21, CD81, and CD225. CD21, or complement 
receptor 2 (CR2), binds to cleavage products of C3 complement 
component and conveys signals through CD19, thereby lower-
ing the threshold for B-cell activation. CD19 also strengthens 
signals generated by the B-cell antigen receptor (BCR) and by 
CD40, which is activated by CD40 ligand (CD40L)-expressing T 
cells (8–10). Another complement receptor that is expressed on 
B cells – CD35 (CR1) – has been proposed to deliver inhibitory 
signals, thus opposing CD21 signals in the regulation of B-cell 
activation (11).
Fcγ receptor IIB (FcγRIIB) and members of sialic acid-
binding immunoglobulin-type lectins (Siglecs) are other 
inhibitory receptors. FcγRIIB, a low-affinity receptor for the Fc 
fragment of immunoglobulin G (IgG), conveys inhibitory signals 
when cross-linked by IgG-containing immune complexes (12). 
Moreover, Siglecs are a family of immune receptors that recog-
nize sialic acids attached to proteins. B cells express only two 
of them, CD22 (Siglec 2) and Siglec 10. Upon activation, CD22 
recruits phosphatases that dephosphorylate several proteins, 
such as CD19, thus switching off B-cell activation. Although less 
studied, Siglec 10 presumably mediates inhibitory signals in a 
similar way to CD22 (4).
The multidimensional role of B cells in systemic autoimmune 
diseases has been progressively recognized (13). Increasing evi-
dence suggests that B cells contribute to autoimmune responses 
by a series of antibody-independent mechanisms, which include 
antigen presentation to T cells and proinflammatory cytokine 
secretion (14). More recently, a population of IL-10-producing 
B cells with the ability to suppress autoimmune responses has 
been characterized in humans (15). These so-called regulatory B 
cells, which are enriched within the subpopulation of transitional 
B cells – immature B cells in transition to secondary lymphoid 
organs, have been shown to be numerically and/or functionally 
disturbed in patients with systemic autoimmune diseases, such 
as rheumatoid arthritis (RA) and systemic lupus erythematosus 
(SLE) (16, 17).
The present study was aimed at evaluating whether B-cell 
subpopulations from SSc patients, including transitional B cells, 
present alterations in frequency, phenotype, and/or expression 
of activating and inhibitory receptors compared with those from 
healthy subjects.
Materials and Methods
study subjects
Thirty-one patients meeting the American College of Rheumatology 
criteria for SSc (18) and 53 healthy controls were recruited. The 
involvement of different systems or organs was evaluated with the 
Modified Medsger scale (19). Table 1 shows the main clinical and 
demographic characteristics of both groups. Blood samples (50 ml) 
were drawn by venous puncture for B-cell phenotyping. Due to the 
limited amount of sample, only some parameters could be assessed 
for each individual. For the expression levels of CD86, CD40, major 
histocompatibility class II (MHC II) molecules, CD35, CD21, CD22, 
and Siglec 10 on B cells, sex- and age-matched SSc patients and 
healthy controls groups were compared. The study was approved 
by the Ethical Committees of the Hospital Clínico and Facultad 
de Medicina, Universidad de Chile, and all subjects gave written 
informed consent in accordance with the Declaration of Helsinki.
B-cell Phenotyping
We characterized B cells using the following monoclonal anti-
human antibodies: anti-CD19 FITC, CD19 Alexa Fluor 700, 
CD24 PE-Cy7, CD38 APC, CD27 APC, CD86 PE-Cy5, CD25 
TaBle 1 | Main demographic and clinical characteristics of the systemic 
sclerosis patients and healthy controls recruited for this study.
characteristics Patients 
(n = 31)
controls 
(n = 53)
Female/male 23/8 28/25
Age 49.3 ± 11.8 40.0 ± 13.7
Disease duration, months (mean ± SD) 102.2 ± 107.2
lcSSc/dcSSc 22/9
Rodnan score (mean ± SD) 13.9 ± 6.0
ANA positivity, n (%) 31 (100)
ANA pattern,an (%)
Speckled 10 (32.3)
Nucleolar 8 (25.8)
Homogeneous 9 (29.0)
Centromere 14 (45.2)
Anti-Scl-70 positivity, n (%) 6 (19.4)
Organ involvement,bn (%)
Peripheral vascular 16 (51.6)
Skin 29 (93.5)
Gastrointestinal tract 27 (90.0)
Lung 21 (70)
Heart 16 (51.6)
Kidney 4 (12.9)
Therapy
Prednisone 3/31
Azathioprine + prednisone 2/31
Methotrexate 3/31
d-penicillamine 1/31
Methotrexate + d-penicillamine 1/31
Methotrexate + d-penicillamine + prednisone 1/31
Hydroxychloroquine 4/31
Methotrexate + hydroxychloroquine 1/31
Only symptomatic treatment 15/31
SD, standard deviation; lcSSc, limited cutaneous systemic sclerosis; dcSSc, diffuse 
cutaneous systemic sclerosis; ANA, antinuclear antibodies.
aSome patients have more than one pattern.
bDefined as a Modified Medsger scale value ≥1.
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PE-Cy7, CD1d PE, CD21 PE, CD22 PE, CD35 PE, Siglec 10 PE 
(Biolegend, USA), CD40 FITC, IL-10 PE, MHC II APC eFluor 
780 (eBioscience, USA), and FcγRII PE (clone 7.3; Fitzgerald 
Industries International, USA). For the cell surface staining 
procedure, peripheral blood mononuclear cells (PBMCs) were 
obtained from blood samples by density gradient centrifugation 
with Lymphoprep (Stemcell Technologies, Canada) and either 
stained freshly or cryopreserved in liquid nitrogen until use. Cells 
were incubated with fluorochrome-labeled antibodies for 30 min 
at 4°C, washed, and fixed before acquisition on a FACSCalibur 
or FACSAria III flow cytometer (BD Biosciences). Data were 
analyzed with FloJo 7.6 Software (USA).
For cytokine production assays, untouched B cells were iso-
lated from whole blood (EasySep, Stemcell Technologies) and 
cultured in RPMI 1640 medium supplemented with 10% fetal 
bovine serum (HyClone, Thermo Scientific, USA) at 1 ×  106 
cells/ml in 96-well plates with 50 ng/ml phorbol 12-myristate 
13-acetate (PMA), 1 μg/ml ionomycin (Sigma-Aldrich, USA), 
and 1 μg/ml brefeldin A (eBioscience) for 5 h at 37°C and 5% 
CO2. For intracellular detection of IL-10 production on B-cell 
subpopulations, cells were stained with anti-CD19, anti-CD38, 
and anti-CD24 antibodies, fixed and permeabilized with 
Permeabilization Buffer (eBioscience), and incubated with an 
anti-IL-10 antibody for flow cytometry analysis. Fluorescence 
minus one (FMO) staining controls were used to exclude 
non-specific background staining. Culture supernatants were 
collected for detection of IL-10 and IL-6 levels by ELISA 
(eBioscience).
statistical analyses
All the study variables were tested for normal distribution with 
the D’Agostino-Pearson omnibus test. Differences between 
SSc patients and healthy control groups, or between groups of 
patients, were analyzed using the two-tailed unpaired Student’s 
t-test or Mann–Whitney U test, when appropriate. For matched 
groups, the two-tailed paired Student’s t-test or Wilcoxon signed-
rank test were used, when appropriate. To examine the relation-
ship between continuous variables, linear regression analyses 
were performed. For statistic analyses and graphics, Stata 12 and 
GraphPad Prism 5 softwares were used.
results
altered Frequencies of B-cell subpopulations in 
Peripheral Blood of systemic sclerosis Patients
To investigate whether the frequency of different B-cell subpopula-
tions is altered in peripheral blood of SSc patients, we analyzed 
them by flow cytometry. A region was set to define the lymphocytic 
population according to forward and side scatter patterns. B cells 
were defined as CD19+ cells, and a second region was set for them. 
Finally, CD24 and CD38 expression was used to discriminate transi-
tional (CD24highCD38high) from naive (CD24intCD38int) and memory 
(CD24highCD38−) B cells, as previously described (16) (Figure 1A).
An increased percentage of CD19+ B cells was found 
in PBMC of SSc patients compared with healthy controls 
(Figure 1B). Since the relative frequency of memory B cells was 
dramatically decreased within SSc patients’ B cells, the observed 
FigUre 1 | Frequencies of B-cell subpopulations in systemic sclerosis patients. (a) Flow cytometry gating strategy to identify transitional B cells 
(CD19+CD24highCD38high), naive B cells (CD19+CD24intCD38int), and memory B cells (CD19+CD24highCD38−). (B) Percentage of CD19+ B cells within peripheral blood 
mononuclear cells (PBMC) in healthy controls (HC) (n = 24) and systemic sclerosis (SSc) patients (n = 24). (c) Percentage of transitional, naive, or memory B-cell 
subpopulations within total CD19+ B cells in HC (white circles) (n = 31) and SSc patients (gray circles) (n = 30). *P < 0.05, ***P < 0.001, Mann–Whitney U test.
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increase in the percentage of total B cells can be explained by 
an expansion of naive B cells. Interestingly, the percentage of 
transitional B cells among total B cells was also increased in the 
peripheral blood of SSc patients compared with healthy subjects 
(Figure 1C).
B cells from systemic sclerosis Patients 
exhibit an activated Phenotype
To evaluate whether B cells from SSc patients exhibit an activated 
phenotype, the surface expression of MHC II and CD86 molecules, 
involved in antigen presentation and costimulation, respectively, 
and upregulated upon B-cell activation, was measured (Figure 2). 
Although very low, the expression of CD86 was elevated in B 
cells from SSc patients, particularly in the transitional and naive 
B-cell subpopulations, when compared with healthy subjects 
(Figure 2B). In contrast, no differences were observed in MHC 
II expression (Figure 2C).
IL-6 and IL-10 are two B-cell-secreted cytokines that have 
been involved in the SSc fibrotic process (2). These cytokines were 
assessed in isolated and stimulated B cells as an estimation of their 
activation status. No differences were observed in the levels of 
IL-6 secreted by B cells from SSc patients and healthy controls 
(Figure 3A). However, SSc patients exhibited a significantly lower 
IL-10 secretion in comparison to healthy subjects (Figure 3B). 
To explore which B-cell subpopulation was responsible for this 
decrease in IL-10 production, intracellular IL-10 expression 
was evaluated by flow cytometry. The majority of IL-10+ cells 
was found within transitional B cells, both in SSc patients and 
healthy controls, which is in accordance with previous reports 
(Figure 3C) (16). Of note, the percentage of IL-10+ B cells was 
reduced in all B-cell subpopulations of SSc patients (Figure 3D). 
To further characterize this finding, we studied in a subset 
of seven patients and eight healthy subjects the frequency of 
CD25highCD27highCD86highCD1dhigh B cells, since this population 
has been described to express high levels of IL-10 (and also TGF-
β) and to exhibit strong regulatory properties (20). In accordance 
with the decreased frequencies of IL-10+ B cells, SSc patients pre-
sented reduced percentages of CD25highCD27highCD86highCD1dhigh 
B cells compared with healthy controls (Figure 3E).
B cells from systemic sclerosis Patients 
exhibit a shift in the Balance of activating 
and inhibitory receptors
The activated phenotype displayed by B cells from SSc patients 
could be caused by an overexpression of molecules involved in 
B-cell activation. To test this possibility, the expression of three 
molecules that participate in B-cell activation was measured by 
flow cytometry: CD19, CD21, and CD40. In accordance with 
previous reports (21), B cells from SSc patients displayed a high 
expression of CD19 not only in naive and memory subpopulations 
but also in the transitional subset (Figure 4A). The expression of 
CD19 on total B cells and on each subpopulation was even higher 
in a subset of SSc patients with anti-Scl-70 antibodies, which is 
mainly associated with dcSSc (Figure 4B). In contrast, no differ-
ences were observed when comparing CD21 expression on differ-
ent B-cell subpopulations from SSc patients and healthy controls 
(Figure 4C). Regarding CD40, increased expression levels were 
observed in total B cells as well as in all B-cell subpopulations 
from SSc patients (Figure 4D).
To find out if a defective expression of inhibitory receptors could 
be associated with the B-cell hyperactivity observed in SSc patients, 
the surface expression of CD22, Siglec 10, CD35, and FcγRIIB 
was examined on B cells from SSc patients and healthy subjects. 
Neither CD22 nor Siglec 10 showed altered expression levels in any 
of the B-cell subpopulations from SSc patients that were studied 
(Figures 5A,B). In contrast, SSc patients exhibited lower levels of 
CD35 expression in CD19+ B cells, in particular in the memory 
compartment (Figure 5C). Moreover, the subset of patients with 
anticentromere antibodies, which associate with lcSSc, showed 
an increased expression of CD35 in total B cells and in all sub-
populations (Figure 5D). Unexpectedly, FcγRIIB expression was 
found to be significantly increased on naive and transitional B-cell 
subsets, but not on memory B cells, from SSc patients (Figure 5E). 
FigUre 2 | surface expression of cD86 and major histocompatibility 
class ii (Mhc ii) molecules on B cells from systemic sclerosis 
patients. (a) Representative histograms of the expression of CD86 and 
MHC II on transitional (dotted line), naive (dashed line), or memory B cells 
(solid line). The shaded curve represents the fluorescence minus one (FMO) 
control staining. (B,c) Expression of CD86 (B) and MHC II (c) on total 
CD19+ B cells, transitional B cells (Trans), naive B cells and memory B cells in 
healthy controls (HC, white circles) (n = 19) and systemic sclerosis patients 
(SSc, gray circles) (n = 19). *P < 0.05, Wilcoxon signed-rank test. MFI, mean 
fluorescence intensity.
FigUre 3 | reduced il-10-expressing B-cell frequencies in systemic sclerosis patients. (a–D) Isolated B cells from healthy controls (HC) or systemic 
sclerosis patients (SSc) were stimulated for 5 h with PMA and ionomycin. IL-6 levels (a) and IL-10 levels (B) secreted by B cells from HC (n = 22) or SSc (n = 22) 
were determined by ELISA and compared with the Mann–Whitney U test. (c) Representative plots of the percentage of CD19+IL-10+ B cells within transitional (left), 
naive (middle), and memory (right) populations. The small inserts on each plot represent the background percentages, as determined by the fluorescence minus one 
(FMO) control staining. (D) Graph summarizing the percentages of CD19+IL-10+ cells among total, transitional (Trans), naive, and memory B cells in HC (white 
circles) (n = 24) and SSc (gray circles) (n = 15) groups. Statistic comparisons were made using the unpaired Student’s t-test. (e) Peripheral blood mononuclear cells 
from HC (n = 8) and SSc patients (n = 7) were stained and analyzed for the presence of CD25highCD27highCD86highCD1dhigh B cells and compared with the 
Mann–Whitney U test. The upper panel represents the gating strategy to identify the subpopulation. Numbers outside and inside the gates indicate the percentages 
of gated cells from the total or previously gated B cells, respectively. *P < 0.05, **P < 0.01, ***P < 0.001.
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Of interest, patients exhibiting peripheral vascular alterations, as 
assessed by the Modified Medsger scale, showed a low expression 
of CD22 and CD35 in total B cells and in all B-cell subpopulations 
(Figure 6), suggesting a critical role of inhibitory molecules on B 
cells in the vascular component of this disease.
Discussion
In the present study, we found important alterations in the 
frequency of different B-cell subpopulations and in the balance 
between activating and inhibitory molecules expressed by these 
B-cell subsets in SSc patients. SSc patients exhibit a bias in the 
distribution of B-cell subpopulations toward an increase in the 
relative frequency of naive cells and a reduction of the memory 
compartment. These results, as well as the increase in the per-
centage of CD19+ B cells within PBMC, are in agreement with 
a previous study in Japanese patients (21). However, this study 
describes for the first time an increase in the proportion of the 
transitional B-cell subpopulation in SSc patients. Similar findings 
have been shown for other autoimmune diseases, such as SLE and 
primary Sjögren’s syndrome (22).
Although it has been suggested that an expansion of immature 
forms of B cells in these conditions could be caused by failures 
in early tolerance checkpoints (23), some of these autoreactive 
transitional B cells could correspond to IL-10-secreting regula-
tory B cells. Furthermore, we found a reduced percentage of 
IL-10+ B cells in the peripheral blood of SSc patients, not only in 
the transitional subpopulation but also in memory and naive B 
FigUre 4 | expression of the activation molecules cD19 (a,B), cD21 (c), and cD40 (D) in B cells from systemic sclerosis patients (n = 29, 24, and 19, 
respectively) and healthy subjects (n = 28, 24, and 19, respectively). (a,c,D) Left: representative histograms of the expression of each molecule on 
transitional (dotted line), naive (dashed line), or memory B cells (solid line). The shaded curve represents the fluorescence minus one (FMO) control staining. Right: 
graphs summarizing the expression of each molecule on total CD19+ B cells, transitional B cells (Trans), naive B cells, and memory B cells in healthy controls (HC, 
white circles) and systemic sclerosis patients (SSc, gray circles). (B) Expression of CD19 in total B cells from HC and SSc patients classified according to the 
presence of anti-Scl-70 antibodies. *P < 0.05, **P < 0.01, ***P < 0.01. Mann–Whitney U test for graphs in (a,c), Wilcoxon signed-rank test for graphs in (D), and 
unpaired Student’s t-test for graph in (B). MFI, mean fluorescence intensity.
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FigUre 5 | expression of the inhibition receptors cD22 (a), siglec 10 (B), cD35 (c,D), and FcγriiB (e) in B cells from systemic sclerosis patients 
(n = 24, 24, 24, and 30, respectively) and healthy subjects (n = 24, 24, 24, and 25, respectively). (a–c,e) Left: representative histograms of the expression 
of each molecule on transitional (dotted line), naive (dashed line), or memory B cells (solid line). The shaded curve represents the fluorescence minus one (FMO) 
control staining. Right: graphs summarizing the expression of each molecule on total CD19+ B cells, transitional B cells (Trans), naive B cells, and memory B cells in 
healthy controls (HC, white circles) and systemic sclerosis patients (SSc, gray circles). (D) Expression of CD35 in SSc patients according to the presence of 
anticentromere antibodies (ACA). *P < 0.05, ***P < 0.001. Paired Student’s t-test for graphs in (a,c), Wilcoxon signed-rank test for graphs in (B), and unpaired 
Student’s t-test for graphs in (D,e). MFI, mean fluorescence intensity.
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cells. Moreover, SSc patients also exhibited reduced percentages 
of CD25highCD27highCD86highCD1dhigh B cells, a B-cell subpopula-
tion able to suppress CD4+ T-cell proliferation (20). Alterations in 
regulatory B-cell functions have been observed in other autoim-
mune diseases (16, 17, 24), and SSc may not be an exception; 
however, functional analysis, such as T-cell responses-inhibition 
assays, should be performed before drawing such conclusion.
B cells from SSc patients have been reported to present an acti-
vated phenotype, which leads to an overproduction of Ig, includ-
ing autoantibodies, and an active production of cytokines, such as 
profibrotic IL-6 (25). In the present study, we demonstrated that 
naive and transitional B cells from SSc patients exhibit an activated 
phenotype, revealed by an increased expression of CD86 compared 
with healthy controls. In contrast with previously reported results, 
this difference was not detected in memory B cells (21). Resting 
naive B cells have been described to cause an incomplete activation 
of T cells, in part, due to the lack of expression of CD86, which can 
be restored after stimulation (26, 27). Therefore, an upregulation of 
CD86 on activated naive B cells could contribute to SSc pathogen-
esis by activating autoreactive T cells, which in turn stimulate the 
secretion of profibrotic cytokines by fibroblasts (28). In contrast, 
regulatory B cells expressing markers of transitional B cells are 
active promoters of tolerance, as they are able to induce regulatory 
T cells, a function that is largely dependent on CD86 (24). The 
impact of the increased CD86 expression found in transitional B 
cells from SSc patients requires further investigation.
The activated phenotype of B cells in SSc has been attributed 
to an increased expression of the activating molecules CD19 and 
CD21 (29). In addition, a polymorphism in the CD22 coding gene 
that is associated with a decreased expression of this receptor on B 
cells has been reported to be more frequent in a subset of Japanese 
lcSSc patients (30). Similarly, in the tight skin TSK/+ murine model 
of SSc, hyperresponsive B cells depend on an exacerbated activity 
of CD19 and an impaired counterregulation by CD22 (31, 32). In 
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FigUre 6 | expression levels of cD22 (a) and cD35 (B) on total B cells 
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the results presented herein, an increased expression of CD19 and 
CD40, but not of CD21, was found in SSc B cells. The differences 
observed between this study and previous ones, regarding the 
expression of B-cell surface molecules such as CD40, CD21, and 
CD86 or the secretion of IL-10 and IL-6 by SSc B cells, could be 
attributed to different experimental settings or to the composition 
of the study group, in terms of the proportion of patients present-
ing lcSSc or dcSSc, as well as the undergoing therapy (21, 29). 
Indeed, decreased expression of CD40 and augmented levels of 
CD22 were found in patients receiving steroids (data not shown).
On the other hand, although no differences were found in the 
expression of CD22 or Siglec 10 on B cells from SSc patients or 
healthy subjects, a reduced expression of CD35 was detected in 
memory B cells from SSc patients. A reduced expression of this 
inhibitory complement receptor has been previously reported 
for other autoimmune diseases, such as SLE and RA, but never 
before for SSc (33–35). On human B cells, CD35 inhibits the 
BCR- and CD40-induced increase in cytoplasmic Ca2+ levels, 
proliferation, and antibody secretion (11, 33). This suggests a 
role of CD35 as a late checkpoint in preventing the maturation 
and differentiation of autoreactive B cells, a function that could 
be altered in autoimmune diseases such as SSc (6). In this sense, 
it is remarkable to note that in this group of patients, expression 
levels of molecules involved in the regulation of B-cell activity are 
associated with different subsets of patients. For instance, patients 
carrying anti-Scl-70 antibodies, which are characteristic of dcSSc, 
exhibited high expression levels of CD19 while patients carrying 
anticentromere antibodies, which are related to lcSSc, showed 
increased expression levels of CD35. The immunologic basis of 
these findings remains obscure for us.
Intriguingly, naive and transitional B cells from SSc patients 
showed high expression levels of the inhibitory receptor FcγRIIB. 
Our group and others have described that in autoimmune dis-
eases, such as RA and SLE, B cells exhibit a reduced expression 
of this receptor in the memory subpopulation, associated to 
high levels of autoantibodies (34–38). Moreover, the absence of 
FcγRIIB specifically on B cells predisposes for the development of 
lupus and arthritis in animal models, highlighting its role as a cru-
cial molecule for the control of autoimmune humoral responses 
(39). Although circulating human transitional B cells have been 
initially described to express moderate levels of FcγRIIB, the 
function of this receptor in transitional B cells remains unknown 
(22). A more recent publication reports a subpopulation of mouse 
IL-10-secreting B cells that expresses high levels of FcγRIIB, which 
endows these cells with the ability for an efficient endocytosis of 
immune complexes and inhibition of CD4+ T-cell responses. 
The authors postulate that by capturing immune complexes, 
these FcγRIIBhigh B cells may attenuate the activation of immune 
responses (40). It remains unclear how the increased expression 
of FcγRIIB on the transitional subpopulation could be involved 
in the alterations observed in SSc B cells. One possibility is that it 
may be a compensatory mechanism triggered after the develop-
ment of an exacerbated humoral response. Another explanation 
is that FcγRIIB could inhibit IL-10 secretion by transitional B 
cells after binding autoantibody-containing immune complexes, 
thus precluding its regulatory functions.
Altogether, this study demonstrates alterations in the frequen-
cies and activation status of different B-cell subpopulations from 
SSc patients, including for the first time an analysis of the transi-
tional B-cell subpopulation. We are currently carrying out in vitro 
experiments in order to uncover the mechanisms through which 
these abnormalities affect the function of B cells in this disease as 
well as key signaling molecules involved.
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